Eli Lilly Shares Rise After Retatrutide Trial Results
Shares rose 1.21% to $1,297.37 at 11:24 a.m. ET after Reuters reported that experimental retatrutide beat Ozempic on weight loss and blood sugar control.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.